Abstract
LEARNING POINT FOR CLINICIANS Hypertrophic pachymeningitis (HP) is characterized by a thickening of the dura mater that in some cases has been related to systemic diseases. Some hearing loss may be the first clinical manifestation of PH as a form of ANCA-positive vasculitis limited to the brain. Treatment with rituximab appears to be a good therapeutic option for these cases.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: QJM : monthly journal of the Association of Physicians
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
